Clinical Trial Update: Immunotherapy With Autologous Tumor Lysate-Loaded Dendritic Cells In Patients With Newly Diagnosed Glioblastoma Multiforme [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 trial evaluating an autologous tumor lysate-loaded dendritic cell vaccine in patients with newly diagnosed glioblastoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma

Drugs mentioned

• Autologous tumor lysate-loaded dendritic cell vaccine (dendritic cell vaccine (autologous tumor lysate-loaded))

Snippet

Sponsor: Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta | Conditions: Glioblastoma | Phase 1, Phase 2 | Status: COMPLETED